Congress targets counterfeit pill supply chain with machine tracking and enforcement
H.R. 8005 — Stop Pills That Kill Act · Filed by Gabe Evans (R-CO) · Introduced Mar 19, 2026 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Controlled Substances Act to regulate tableting and encapsulating machines and their critical parts (punches, dies) by requiring serial numbers, tracking sales, and criminalizing tampering with or knowingly distributing machines intended for illicit drug manufacturing. It also strengthens penalties for manufacturing counterfeit pills laced with fentanyl, methamphetamine, or other synthetic opioids, and requires the DEA to develop an enforcement and education plan with annual reporting to Congress.
Why we flagged it
The bill's core mechanism is regulatory and criminal enforcement targeting the supply chain for pill-making equipment used in illicit drug manufacturing. It is fundamentally a public health and law enforcement measure designed to disrupt counterfeit opioid production.
What the text implies
- Serial number requirements on machines manufactured before enactment (180-day grace period) may create compliance burden on legitimate manufacturers and distributors of tableting equipment, potentially raising costs for pharmaceutical and supplement industries.
- The Attorney General's authority to designate additional 'critical parts' via rulemaking (without prior enumeration) creates an open-ended regulatory expansion that could capture components not currently contemplated, affecting a broader supply chain.
- Extraterritorial jurisdiction provisions (Section 1009(c)) criminalize manufacture or distribution of machines outside the U.S. if intended for illicit U.S. importation, extending U.S. law enforcement reach into foreign manufacturing and potentially creating diplomatic or trade friction.
- Annual reporting requirement through 2031 creates ongoing data collection on counterfeit pills, which may reveal geographic trafficking patterns and inform future enforcement but also establishes a permanent surveillance/monitoring infrastructure.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill directly addresses the counterfeit pill crisis by restricting access to equipment used to manufacture fentanyl-laced pills and increasing criminal penalties for those who knowingly supply such equipment. Citizens benefit from reduced availability of counterfeit pills and stronger law enforcement tools to combat synthetic opioid trafficking, which has caused tens of thousands of overdose deaths.
Named in the bill
Drug Enforcement Administration (DEA), Attorney General, Department of Justice, Office of National Drug Control Policy, Food and Drug Administration (FDA), United States Sentencing Commission, Controlled Substances Act
Where it stands
- Mar 19, 2026 — Introduced · Congress.gov: “Introduced in House”
- Mar 19, 2026 — Referred to House Committee on Energy and Commerce and House Committee on the Judiciary · Congress.gov: “Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a…”
- Jul 15, 2026 — Markup held in committee · Congress.gov: “Subcommittee Consideration and Mark-up Session Held”
- Jul 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 43 - 6”
- Sep 15, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote”
- Sep 15, 2026 — Floor vote scheduled · Congress.gov: “Mr. Guthrie moved to suspend the rules and pass the bill, as amended”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $260,000 in lobbying spend. A filing names 25 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Gabe Evans, the sponsor, reported $1,523,467 in PAC receipts in the 2026 cycle.
- American Society of Health-system Pharmacists — $260,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (13,675 characters) on Aug 20, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress targets counterfeit pill supply chain with machine tracking and enforcement” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8005 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.